Pathological types and clinical efficacy of 684 patients with breast cancer above 65 years in Suqian

Objective To investigate the clinical pathological types and efficacy of senile breast cancer in Suqian area. Methods The clinical data of breast cancer patients aged above 65 years old in Suqian area were collected. The pathological types and therapy were evaluated and summarized. Results A total of 684 cases were divided into two groups by pathological types, neoadjuvant therapy group (n=306) and surgery group (n=378). The one-year, 3-year and 5-year disease-free survival (DFS) and overall survival (OS) were compared between the two groups, 132 cases with Luminal A, accounting for 19.3% (132/684), 324 cases with Luminal B, accounting for 47.37% (324/684), of 283 cases of Luminal B Ⅰ, accounting for 41.37% (283/684), 41 cases of Luminal B Ⅱ, accounting for 5.99% (41/684); 132 cases with Her-2 over-expression, accounting for 19.30%; 96 cases with Triple negative breast cancer (TNBC), accounting for 14.04%. The short-term efficacy of neoadjuvant therapy of 306 patients: among the patients with neoadjuvant chemotherapy, 22 cases of pCR, 30 cases of cCR, 106 cases of PR, 80 cases of SD, 28 cases of PD; among the patients with neoadjuvant endocrine therapy, 3 cases of pCR, 2 cases of cCR 6 cases of PR, 2 cases of SD, 20 cases of PD; among of patients with neoadjuvant targeted therapy, 1 case of pCR, 1 case of cCR, 5 cases of PR, 0 case of SD, 0 case of PD. The long-term efficacy of neoadjuvant therapy of 306 patients; 1-year DFS and OS were 100%, 2-year DFS was 84.72%, 3-year DFS was 76.31%, 5-year DFS was 66.41%; , 2-year OS was 94.72%, 3-year OS was 86.31%, 5-year OS was 76.41%. The long-term efficacy of surgery therapy of 378 patients: 1-year DFS was 92.73%, 2-year DFS was 76.59%, 3-year DFS was 60.63%, 5-year DFS was 57.22%, 1-year OS was 100%, 2-year OS was 85.65%, 3-year OS was 74.71%, 5-year OS was 48.33%. Conclusions DFS and OS of senile patients with breast cancer who underwent neoadjuvant therapy were significantly superior to those of surgery therapy. Senile patients with breast cancer of Luminal B were more than those of Luminal A in Suqian area, and the proportion of Her-2 over expression and triple negative breast cancer is consistent with that reported at home and abroad. Key words: Suqian; Senile breast cancer; Pathological type; Efficacy